Chlamydia pneumoniae polynucleotides and uses thereof

Abstract

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae , such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular Chlamydia pneumoniae , infections.

1 . A composition of matter comprising:
 (a) an isolated polynucleotide, or a fragment thereof, having a nucleotide sequence of a  Chlamydia pneumoniae  genome comprising:
 (1) the nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1, 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF), or a fragment thereof, of a  Chlamydia pneumoniae  genome comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 
 (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 
 (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide encoding a heterologous polypeptide; 
   (b) a recombinant vector comprising:
 (1) the a nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF) of a  Chlamydia pneumoniae  genome comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, 
 
 (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence, or a fragment thereof; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 
 (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide encoding a heterologous polypeptide; 
   (c) a genetically engineered host cell comprising:
 (1) the nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF), or a fragment thereof, of a  Chlamydia pneumoniae  genome comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 
 (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 
 (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide encoding a heterologous polypeptide; 
   (d) an isolated polypeptide, or a fragment thereof, encoded by:
 (1) the nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF) of a  Chlamydia pneumoniae  genome comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 
 (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 
 (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide, encoding a heterologous polypeptide; 
   (e) an isolated polypeptide comprising the following polypeptides or fragments thereof:
 (1) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (2) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (3) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (4) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (5) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (6) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (7) a  Chlamydia pneumoniae  polypeptide involved in metabolism of fatty acids; 
 (8) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (9) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (10) a  Chlamydia pneumoniae  transport polypeptide; 
 (11) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (12) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (13) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (14) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (15) a  Chlamydia pneumoniae  lipoprotein; 
 (16) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (17) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (18) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (19) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (20) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (21) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (22) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (23) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (24) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis;    
 (25) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (26) a polypeptide having at least 80% homology or identity to a polypeptide selected from any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof; 
 (27) a fusion protein comprising any of the aforementioned polypeptides, or fragments thereof; 
   (f) a DNA immunogenic composition comprising a recombinant vector comprising:
 (1) the a nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF), or a fragment thereof, comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 
 (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 
 (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide encoding a heterologous polypeptide; 
   (g) an isolated antibody that immunospecifically binds to a polypeptide comprising following polypeptides or fragments thereof:
 (1) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (2) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (3) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (4) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (5) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (6) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (7) a  Chlamydia pneumoniae  polypeptide involved in metabolism of fatty acids; 
 (8) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (9) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (10) a  Chlamydia pneumoniae  transport polypeptide; 
 (11) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (12) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (13) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (14) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (15) a  Chlamydia pneumoniae  lipoprotein; 
 (16) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (17) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (18) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (19) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (20) a Chlamydia  pneumoniae  lipid A component-related polypeptide; 
 (21) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (22) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (23) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (24) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis;    
 (25) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (26) polypeptides and fragments thereof having at least 80% homology or identity to a polypeptide selected from any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (27) a fusion protein comprising any of the aforementioned polypeptide. 
   
     
     
         2 . The composition of matter according to  claim 1 , wherein the DNA immunogenic composition directs the expression of a neutralizing epitope of  Chlamydia pneumoniae.    
     
     
         3 . The composition of matter according to  claim 1 , wherein said polypeptide immunoreacts with seropositive serum from an individual infected by  Chlamydia pneumoniae.    
     
     
         4 . The composition of matter according to  claim 1 , wherein said composition of matter comprises a polypeptide and a pharmaceutically acceptable carrier. 
     
     
         5 . The composition of matter according to  claim 3 , wherein said composition of matter comprises a pharmaceutically acceptable carrier and said polypeptide. 
     
     
         6 . The composition of matter according to  claim 4 , wherein said composition of matter is immunogenic. 
     
     
         7 . The composition of matter according to  claim 5 , wherein said composition of matter is immunogenic. 
     
     
         8 . The composition of matter according to  claim 7 , wherein said polypeptide elicits an immune response and the production of antibodies against said polypeptide. 
     
     
         9 . The composition of matter according to  claim 8 , wherein said polypeptide is any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297 or fragments thereof. 
     
     
         10 . The composition of matter according to  claim 8 , wherein said polypeptide further comprises a heterologous polypeptide or protein. 
     
     
         11 . The composition of matter according to  claim 9 , wherein said polypeptide further comprises a heterologous polypeptide or protein. 
     
     
         12 . The composition of matter according to  claim 10 , wherein said heterologous polypeptide is capable of eliciting an immune response in humans or animals. 
     
     
         13 . The composition of matter according to  claim 11 , wherein said heterologous polypeptide is capable of eliciting an immune response in humans or animals. 
     
     
         14 . The composition of matter according to  claim 1 , wherein said composition of matter comprises a pharmaceutical composition comprising an immunizing amount of an isolated polypeptide having at least 80% homology or identity to a polypeptide selected from any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297 or a fragment thereof and a pharmaceutically acceptable diluent. 
     
     
         15 . The composition of matter according to  claim 14 , wherein said polypeptide is any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297. 
     
     
         16 . The composition of matter according to  claim 14 , further comprising an adjuvant. 
     
     
         17 . The composition of matter according to  claim 15 , wherein said composition of matter comprises an adjuvant. 
     
     
         18 . The composition of matter according to  claim 1 , wherein said genetically engineered host cell comprises a polynucleotide or a fragment thereof operatively associated with a regulatory sequence that controls gene expression in the host cell. 
     
     
         19 . The composition of matter according to  claim 1 , wherein said antibody immunospecifically binds to said fusion protein. 
     
     
         20 . The composition of matter according to  claim 1 , wherein said polypeptide, or a fragment thereof, or said polynucleotide, or fragment thereof, is provided on a solid support. 
     
     
         21 . The composition of matter according to  claim 1 , wherein said polynucleotide fragment is a probe or primer. 
     
     
         22 . The composition of matter according to  claim 21 , wherein said probe is a sequence of at least 12 nucleotides, at least 20 nucleotides, or at least 100 nucleotides in length and said primer is at least 8 nucleotides, at least 12 nucleotides, at least 15 nucleotides or at least 20 nucleotides in length. 
     
     
         23 . The composition of matter according to  claim 1 , further comprising a container to form a kit. 
     
     
         24 . A method for producing a polypeptide, comprising:
 (a) culturing a genetically engineered host cell under conditions suitable to produce a polypeptide encoded by a polynucleotide, or fragment thereof, and   (b) recovering the polypeptide from the culture,   wherein said genetically engineered host cell comprises:
 (1) the nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF), or a fragment thereof, of a  Chlamydia pneumoniae  genome comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 
 (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 
 (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide encoding a heterologous polypeptide. 
   
     
     
         25 . A method for the detection and/or identification of  Chlamydia pneumoniae  in a biological sample, comprising:
 (a) contacting the sample with a polynucleotide primer in the presence of a polymerase enzyme and nucleotides under conditions which permit primer extension or contacting the sample with a polynucleotide probe under conditions which permit hybridization of complementary base pairs; and   (b) detecting the presence of primer extension products in the sample in which the detection of primer extension products indicates the presence of  Chlamydia pneumoniae  in the sample or detecting the presence of hybridization complexes in the sample in which the detection of hybridization complexes indicates the presence of  Chlamydia pneumoniae  in the sample, wherein said probe or primer comprises a polynucleotide, or a fragment thereof, having a nucleotide sequence of a  Chlamydia pneumoniae  genome comprising:
 (1) the nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634; 
 (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002; 
 (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1; 
 (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1; 
 (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency; 
 (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency; 
 (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF), or a fragment thereof, of a  Chlamydia pneumoniae  genome comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 
 (9) a polynucleotide, or a fragment thereof, or probe which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency; 
 (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of intermediate stringency; 
 (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a Chlamydia  pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a Chlamydia  pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a Chlamydia  pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297. 
 
   
     
     
         26 . A method for the detection and/or identification of  Chlamydia pneumoniae  in a biological sample, comprising:
 (a) contacting the sample with an antibody under conditions suitable for the formation of immune complexes; and   (b) detecting the presence of immune complexes in the sample, in which the detection of immune complexes indicates the presence of  Chlamydia pneumoniae  in the sample, wherein said antibody binds to a polypeptide comprising any one of the following polypeptides or fragments thereof:
 (1) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (2) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (3) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (4) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (5) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (6) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (7) a  Chlamydia pneumoniae  polypeptide involved in metabolism of fatty acids; 
 (8) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (9) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (10) a  Chlamydia pneumoniae  transport polypeptide; 
 (11) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (12) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (13) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (14) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (15) a  Chlamydia pneumoniae  lipoprotein; 
 (16) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (17) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (18) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (19) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (20) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (21) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (22) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (23) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (24) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis;    
 (25) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (26) polypeptides and fragments thereof having at least 80% homology or identity to a polypeptide selected from any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (27) a fusion protein comprising any of the aforementioned polypeptides or fragments thereof. 
   
     
     
         27 . A method of immunizing against  Chlamydia pneumoniae , comprising: administering to a host an immunizing amount of a polypeptide or a DNA immunogenic composition, wherein said DNA immunogenic composition comprises a recombinant vector comprising:
 (1) the nucleotide sequence, or a fragment thereof, of SEQ ID NO: 1;   (2) the nucleotide sequence, or a fragment thereof, contained within the  Chlamydia pneumoniae  genomic DNA in ATCC Deposit No. VR 2634;   (3) the nucleotide sequence, or a fragment thereof, contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002;   (4) a nucleotide sequence, or a fragment thereof, exhibiting at least 99.9% identity with the sequence, or a fragment thereof, of SEQ ID NO: 1;   (5) a nucleotide sequence, or a fragment thereof, exhibiting at least 80% homology to SEQ ID NO: 1;   (6) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency;   (7) a polynucleotide, or a fragment thereof, which hybridizes to SEQ ID NO: 1 or to the  Chlamydia pneumoniae  genomic DNA contained in ATCC Deposit No. VR 2634 under conditions of intermediate stringency;   (8) a polynucleotide, or a fragment thereof, encoding an open reading frame (ORF), or a fragment thereof, comprising:
 (i) a polypeptide sequence, or a fragment thereof, chosen from one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
 (ii) a polypeptide sequence, or a fragment thereof, exhibiting at least 99.9% identity with one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
 (iii) a polypeptide sequence, or a fragment thereof, exhibiting at least 80% homology to one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; 
   (9) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof, under conditions of high stringency;   (10) a polynucleotide, or a fragment thereof, which hybridizes to a polynucleotide, or a fragment thereof, encoding one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, under conditions of intermediate stringency;   (11) a nucleotide sequence, or a fragment thereof, which encodes the following polypeptides or fragments thereof:
 (i) a  Chlamydia pneumoniae  transmembrane polypeptide having between 1 and 3 transmembrane domains; 
 (ii) a  Chlamydia pneumoniae  transmembrane polypeptide having between 4 and 6 transmembrane domains; 
 (iii) a  Chlamydia pneumoniae  transmembrane polypeptide having at least 7 transmembrane domains; 
 (iv) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of sugars and/or cofactors; 
 (v) a  Chlamydia pneumoniae  polypeptide involved in intermediate metabolism of nucleotides or nucleic acids; 
 (vi) a  Chlamydia pneumoniae  polypeptide involved in metabolism of amino acids or polypeptides; 
 (vii) a  Chlamydia pneumoniae  polypeptide having involved in metabolism of fatty acids; 
 (viii) a  Chlamydia pneumoniae  polypeptide involved in the synthesis of the cell wall; 
 (ix) a  Chlamydia pneumoniae  polypeptide involved in transcription, translation, and/or maturation process; 
 (x) a  Chlamydia pneumoniae  transport polypeptide; 
 (xi) a  Chlamydia pneumoniae  polypeptide involved in the virulence process; 
 (xii) a  Chlamydia pneumoniae  polypeptide involved in the secretory system and/or which is secreted; 
 (xiii) a  Chlamydia pneumoniae  polypeptide of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (xiv) a  Chlamydia pneumoniae  surface exposed polypeptide; 
 (xv) a  Chlamydia pneumoniae  lipoprotein; 
 (xvi) a  Chlamydia pneumoniae  polypeptide involved in lipopolysaccharide biosynthesis; 
 (xvii) a  Chlamydia pneumoniae  KDO-related polypeptide; 
 (xviii) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide; 
 (xix) a  Chlamydia pneumoniae  lipid A component-related polypeptide; 
 (xx) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide; 
 (xxi) a  Chlamydia pneumoniae  polypeptide that contains an RGD sequence; 
 (xxii) a  Chlamydia pneumoniae  Type III secreted polypeptide; 
 (xxiii) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide; 
 (xxiv) a  Chlamydia pneumoniae  polypeptide that is not found in  Chlamydia trachomatis ; or 
 (xxv) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297; or 
   (12) a polynucleotide, or a fragment thereof, encoding any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or a fragment thereof, ligated in frame to a polynucleotide encoding a heterologous polypeptide;   and said polypeptide comprises:
 (1) a  Chlamydia pneumoniae  transmembrane polypeptide or a fragment thereof having between 1 and 3 transmembrane domains; 
 (2) a  Chlamydia pneumoniae  transmembrane polypeptide or a fragment thereof having between 4 and 6 transmembrane domains; 
 (3) a  Chlamydia pneumoniae  transmembrane polypeptide or a fragment thereof having at least 7 transmembrane domains; 
 (4) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in intermediate metabolism of sugars and/or cofactors; 
 (5) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in intermediate metabolism of nucleotides or nucleic acids; 
 (6) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in metabolism of amino acids or polypeptides; 
 (7) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in metabolism of fatty acids; 
 (8) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in the synthesis of the cell wall; 
 (9) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in transcription, translation, and/or maturation process; 
 (10) a  Chlamydia pneumoniae  transport polypeptide or a fragment thereof; 
 (11) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in the virulence process; 
 (12) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in the secretory system and/or which is secreted; 
 (13) a  Chlamydia pneumoniae  polypeptide or a fragment thereof of the cellular envelope or outer cellular envelope of  Chlamydia pneumoniae;    
 (14) a  Chlamydia pneumoniae  surface exposed polypeptide or a fragment thereof; 
 (15) a  Chlamydia pneumoniae  lipoprotein or a fragment thereof; 
 (16) a  Chlamydia pneumoniae  polypeptide or a fragment thereof involved in lipopolysaccharide biosynthesis; 
 (17) a  Chlamydia pneumoniae  KDO-related polypeptide or a fragment thereof; 
 (18) a  Chlamydia pneumoniae  phosphomannomutase-related polypeptide or a fragment thereof; 
 (19) a  Chlamydia pneumoniae  phosphoglucomutase-related polypeptide or a fragment thereof; 
 (20) a  Chlamydia pneumoniae  lipid A component-related polypeptide or a fragment thereof; 
 (21) a  Chlamydia pneumoniae  polypeptide or a fragment thereof that contains an RGD sequence; 
 (22) a  Chlamydia pneumoniae  Type III secreted polypeptide or a fragment thereof; 
 (23) a  Chlamydia pneumoniae  cell wall anchored surface polypeptide or a fragment thereof; 
 (24) a  Chlamydia pneumoniae  polypeptide or a fragment thereof that is not found in  Chlamydia trachomatis;    
 (25) any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297, or fragments thereof; 
 (26) polypeptides and fragments thereof having at least 80% homology or identity to a polypeptide selected from any one of ORF 2 to 194, ORF 196 to 226, ORF 228 to 233, ORF 235 to 279, ORF 281 to 290, ORF 292 to 1159, ORF 1161, ORF 1163 to 1254 or ORF 1259 to 1297 or a fragment thereof; or 
 (27) a fusion protein comprising any one of the aforementioned polypeptides or fragments thereof.